Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice

Neoplasia

Volumn 5, Issue 1, 2003, Pages 32-40

  Kisker, Oliver ^a,b   Onizuka, Shinya ^c   Becker, Christian M ^a,d   Fannon, Michael ^a   Flynn, Evelyn ^a   D'Amato, Robert ^a   Zetter, Bruce ^a   Folkman, Judah ^a   Ray, Rahul ^e   Swamy, Narasimha ^f   Pirie Shepherd, Steven ^a,g  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BROWN UNIVERSITY   (United States)

^g Attenuon LLC   (United States)

Author keywords

Angiogenesis; Carcinoma; Macrophages; Pancreas; Vitamin D binding protein

Indexed keywords

ANGIOGENESIS INHIBITOR; MACROPHAGE ACTIVATING FACTOR; VITAMIN D BINDING PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CATTLE; CHORIOALLANTOIS; CONTROLLED STUDY; DEGLYCOSYLATION; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR REGRESSION;

EID: 12244301198     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80015-5     Document Type: Article

References (28)

1. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31.
2. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, and Folkman J (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-28.
3. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, and Folkman J (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-85.
4. O'Reilly MS, Pirie-Shepherd S, Lane WS, and Folkman J (1999). Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285, 1926-28.
5. O'Reilly MS, Rosenthal R, Sage EH, Smith S, Holmgren L, Moses M, Shing Y, and Folkman J (1993). The suppression of tumor metastases by a primary tumor. Surg Forum 44, 474-76.
6. Ray R (1996). Molecular recognition in vitamin D-binding protein. Proc Soc Exp Biol Med 212, 305-12.
7. Yamamoto N, and Kumashiro R (1993). Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. J Immunol 151, 2794-802.
8. Yamamoto N, and Naraparaju VR (1997). Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res 57, 2187-92.
9. Koga Y, Naraparaju VR, and Yamamoto N (1999). Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice. Proc Soc Exp Biol Med 220, 20-26.
10. Korbelik M, Naraparaju VR, and Yamamoto N (1997). Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 75, 202-207.
11. Nguyen M, Shing Y, and Folkman J (1994). Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res 47, 31-40.
12. Swamy N, Roy A, Chang R, Brisson M, and Ray R (1995). Affinity purification of human plasma vitamin D-binding protein. Protein Expr Purif 6, 185-88.
13. Yamamoto N, and Homma S (1991). Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88, 8539-43.
14. Ono M, Torisu H, Fukushi J, Nishie A, and Kuwano M (1999). Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol 43(Suppl), 69-71.
15. Kodelja V, Muller C, Tenorio S, Schebesch C, Orfanos CE, and Goerdt S (1997). Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 197, 478-93.
16. Cao R, Farnebo J, Kurimoto M, and Cao Y (1999). Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 13, 2195-202.
17. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, and Folkman J (1995). Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87, 581-86.
18. Yamamoto N, Naraparaju VR, and Asbell SO (1996). Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res 56, 2827-31.
19. Morton D, Eilber FR, Malmgren RA, and Wood WC (1970). Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68, 158-63.
20. Yamamoto N, Hoober JK, Yamamoto N, and Yamamoto S (1992). Tumoricidal capacities of macrophages photodynamically activated with hematoporphoryin derivative. Photochem Photobiol 56, 245-50.
21. Weiner LM, Moldofsky PJ, Gatenby RA, O'Dwyer J, O'Brien J, Litwin S, and Comis RL (1980). Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma. Cancer Res 48, 2568-73.
22. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, and Old LJ (1985). Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82, 1242-46.
23. 3-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. JNCI 94, 1311-19.
24. Yamamoto N, Naraparaju VR, and Srinivasula SM (1995). Structural modification of serum vitamin-D3 binding protein and immunosuppression in HIV-infected patients. AIDS Res Hum Retroviruses 11, 1373-78.
25. Yang F, Bergeron JM, Linehan LA, Lalley PA, Sakaguchi AY, and Bowman BH (1990). Mapping and conservation of the group-specific component gene in mouse. Genomics 7, 509-16.
26. Yamamoto N, Lindsay DD, Naraparaju VR, Ireland RA, and Popoff SN (1994). A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats. J Immunol 152, 5100-107.
27. O'Reilly MS, Holmgren L, Chen C, and Folkman J (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2, 689-92.
28. Boehm T, Folkman J, Browder T, and O'Reilly MS (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.